ICU · SeaStar Medical Holding Corp · Earnings Call Transcripts & Audio
$3.13
+0.03 (+0.97%)
At close · Sep 10
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company believes that these conditions raise substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$13.79M
Shares
4.41M
SeaStar Medical Holding Corp Earnings Call Transcripts
Quarterly earnings calls for SeaStar Medical Holding Corp (ICU), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
Earnings call
FY26 · Q2
2026-08-12
SeaStar Medical Holding Corp (ICU) Q2 2026 Earnings Call Transcript
Confident tone
QUELIMMUNE pediatric commercial adoption
NEUTRALIZE-AKI pivotal trial enrollment
Adult AKI market opportunity and FDA pathway
Revenue
$615,000
▲ 82% YoY Gross margin
91.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
SeaStar Medical Holding Corp (ICU) Q1 2026 Earnings Call Transcript
Confident tone
Quellimmune pediatric commercial momentum
Neutralize AKI pivotal trial enrollment
SCD platform broader indications
Revenue
$495,000
▲ 68.9% YoY Gross margin
90.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-25
SeaStar Medical Holding Corp (ICU) Q4 2025 Earnings Call Transcript
Confident tone
Pediatric AKI Commercial Expansion (Qualimmune)
Neutralize AKI Pivotal Trial Enrollment (Adult AKI)
SAVE Registry Publication and Clinical Evidence
Revenue
$420,000*
▲ 526.9% YoY Gross margin
97.1%
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
SeaStar Medical Holding Corp (ICU) Q3 2025 Earnings Call Transcript
Confident tone
Neutralize AKI pivotal trial enrollment
Quellimmune commercial launch and pediatric site activation
Neutralize CRS cardiorenal syndrome trial
Revenue
$183,000
▲ 169.1% YoY Gross margin
92.3%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
SeaStar Medical Holding Corp (ICU) Q1 2025 Earnings Call Transcript
Confident tone
QUELIMMUNE pediatric commercial launch
NEUTRALIZE-AKI adult pivotal trial
Cardiac surgery breakthrough device designations
Revenue
$293,000
Diluted EPS
$-4.40
Gross margin
100.0%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
SeaStar Medical Holding Corp (ICU) Q4 2024 Earnings Call Transcript
Confident tone
Quellimmune commercial launch
NeutraLized AKI pivotal study
Pipeline expansion opportunities
Revenue
$67,000*
Gross margin
100.0%
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-12-04
SeaStar Medical Holding Corp (ICU) Q3 2024 Earnings Call
Revenue
$68,000
Diluted EPS
$-11.00
Gross margin
100.0%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-15
SeaStar Medical Holding Corp (ICU) Q2 2023 Earnings Call
Diluted EPS
$-41.00
Audio
Transcript
Slides
8-K10-Q
Showing 1–8 of 8 earnings calls
Key facts
CIK
1831868
CUSIP
81256L302
13F (30d)
11 filings
11 filers
Visit website
Investor relations